🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "significant breakthrough" in the battle against drug-resistant strains of the pathogen, according to scientists.

A Worldwide Health Concern

Gonorrhoea infections are increasing around the world, with data suggesting in excess of 82 million new cases per year. Notably increased rates are seen in the African continent and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune step in the face of growing infection rates, escalating drug resistance and the very limited available drugs presently on offer.”

Health officials are particularly alarmed about the surge in drug-resistant strains. The WHO has designated it as a "priority pathogen". Ongoing monitoring revealed that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Gain Approval

Zoliflodacin, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in mid-December for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Experts anticipate that specific application of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GSK, was also approved in the same week. This drug, which is also used to treat UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This approval marks a huge turning point in the management of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Results and Worldwide Availability

According to findings detailed in a prominent scientific publication, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This places it at an equal footing with the current standard treatment, which involves two antibiotics. The trial included over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the ability to license and sell the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have voiced positive views. The availability of a easy-to-administer therapy such as this is hailed as a "game-changer" for gonorrhoea control. This is deemed essential to alleviate the strain of the illness for individuals and to prevent the spread of untreatable gonorrhoea worldwide.